A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis
Arthritis & Rheumatism2011Vol. 64(3), pp. 843–853
Citations Over TimeTop 1% of 2011 papers
Salvatore De Vita, Luca Quartuccio, Miriam Isola, Cesare Mazzaro, Patrizia Scaini, Marco Lenzi, M. Campanini, Caterina Naclerio, Antonio Tavoni, Maurizio Pietrogrande, Clodoveo Ferri, Maria Teresa Mascia, Paola Masolini, Alen Zabotti, M. Maset, Dario Roccatello, Anna Linda Zignego, Pietro Pioltelli, Armando Gabrielli, Davide Filippini, O. Perrella, S. Migliaresi, Massimo Galli, Stefano Bombardieri, Giuseppe Monti
Abstract
RTX monotherapy represents a very good option for severe CV and can be maintained over the long term in most patients.
Related Papers
- → Use of Plasmapheresis and Partial Plasma Exchange in the Management of Patients with Cryoglobulinemia(1980)134 cited
- → Plasmapheresis in multiple sclerosis(1982)72 cited
- → Plasmapheresis with return of cryoglobulin-depleted autologous plasma (cryoglobulinpheresis) in cryoglobulinemia(1980)72 cited
- → Plasmapheresis with return of cryoglobulin-depleted autologous plasma (cryoglobulinpheresis) in cryoglobulinemia(1980)1 cited
- [Plasmapheresis in clinical practice].(1994)